An open-label, treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory CD30-positive cutaneous T-cell lymphoma

Trial Profile

An open-label, treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory CD30-positive cutaneous T-cell lymphoma

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Feb 2015

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Anaplastic large cell lymphoma; Cutaneous T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top